Probiotic Medilac-S® for the induction of clinical remission in a Chinese population with ulcerative colitis: A systematic review and meta-analysis

Figure 9 Forest plots of the results of fixed effects meta-analysis with 30 studies evaluating the effect of Medilac-S^® in combination with conventional drug therapy on number of participants reporting adverse events. “AE” is the number of participants reporting adverse events within a study and “N” is the total number of participants within the study. The relative risk (RR) and its 95%CI for each study are listed on the right hand side of the graph. The 95%CI for the estimated mean RR for each concomitant drug therapy category is shown as a shaded diamond with the endpoints of the diamond being the CI endpoints. The vertical dashed line at 1 indicates a RR of 1 which occurs when there is no observed difference between the treatment and the control.